Advertisement

Topics

Syndicated Content about Biotechnology, Pharmaceutical and Healthcare

04:59 EST 8th February 2016 | BioPortfolio

Latest global life science, pharmaceutical and healthcare news syndicated from over 50 publishers. 

Showing News Articles 1–25 of 220,000+

Monday 8th February 2016

NICE u-turn backs use of Amgen's Repatha

NICE u-turn backs use of Amgen's Repatha

Mesenchymal stromal cells in renal transplantation: opportunities and challenges

The unique immunomodulatory properties of multipotent mesenchymal stromal cells (MSCs) make them a promising candidate for cell therapy in organ transplantation. Here, the authors review preclinical data that support the potential tolerance-inducing effects of MSCs in transplant models and the results of initial clinical studies in kidney transplantation.

Mineral and bone disorders: Targeting CYP24A1

Proteinuria: New therapeutic strategy for proteinuria

Genetics: GWAS identifies 24 new loci for renal function

Autoimmunity: Mitochondrial function in autoimmune disorders

Chronic kidney disease: Proton pump inhibitors increase risk of CKD

Hypertension: Blood pressure lowering after lacunar stroke

Microbiology: Altered gut microbiota in CKD

BRIEF-Pharma Mar gets IDMC's recommendation to continue phase 3 trial with PM1183

* Independent Data Monitoring Committee recommends to continue unchanged Phase 3 trial with PM1183 in patients with platinum-resistant ovarian cancer

BRIEF-Novozymes changes organizational structure

* Changes in organizational structure and executive leadership team

BRIEF-C-RAD Q4 operating loss widens to SEK 6.1 mln

* Q4 net sales 20.1 million Swedish crowns ($2.37 million) versus 18.6 million crowns year ago

BRIEF-Oasmia submitted marketing authorization application to EMA for Apealea

* Oasmia has submitted a marketing authorization application to the european medicines agency for its lead cancer product apealea Source text for Eikon: Further company coverage:

BRIEF-Biomaxima Jan. 2016 revenue up at 2.1 mln zlotys

* Jan. 2016 revenue 2.1 million zlotys ($531,041) versus 1.7 million zlotys a year ago Source text for Eikon: Further company coverage: ($1 = 3.9545 zlotys) (Gdynia Newsroom)

BRIEF-Genomic Vision to present at Source Capital Group's 2016 disruptive growth & healthcare conference

* To present at source capital group's 2016 disruptive Growth & Healthcare conference Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Stentys initiates commercialization of self-expanding drug-eluting stent for the below-the-knee indication

* Stentys initiates the commercialization of the first self-expanding drug-eluting stent for the below-the-knee indication

BRIEF-Theraclion: First patients treated in routine clinical practice in the UK

* First patients treated in routine clinical practice in the UK

Key step toward custom-made nanoscale chemical factories

Scientists have for the first time reengineered a building block of a geometric nanocompartment that occurs naturally in bacteria. They introduced a metal binding site to its shell that will allow electrons to be transferred to and from the compartment. This provides an entirely new functionality, g...

BRIEF-Visiomed announces registration of MyECG(R) and MyOxyR) by the FDA

* Announces the registration of MyECG(R) and MyOxy(R) by the FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Exclusive: U.S. athletes should consider not attending Olympics if fear Zika: officials

NEW YORK (Reuters) - The United States Olympic Committee told U.S. sports federations that athletes and staff concerned for their health over the Zika virus should consider not going to the Rio 2016 Olympic Games in August.

UPDATE 1-Battling doctor shortage, Indian hospitals offer intensive care from afar

* Electronic intensive care units a growth area for Fortis, Apollo

BRIEF-Innate Pharma to start phase I clinical trial of monalizumab

* Announces the start of phase I clinical trial of monalizumab in combination with durvalumab

BRIEF-Valneva signs new research and development collaboration with GlaxoSmithKline

* Signs new research and development collaboration with GlaxoSmithKline for EB66 cell line

Swiss stocks - Factors to watch on Feb 8

ZURICH, Feb 8 (Reuters) - The following are some of the main factors expected to affect Swiss stocks on Monday.

Akashi Investigating Duchenne Patient Death

Akashi Therapeutics Inc. said it was investigating whether there was a link between its experimental Duchenne muscular dystrophy (DMD) therapy HT-100 and the death of a patient who had been participating in the firm's HALO trial when he experienced...


Quick Search
Advertisement